Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT06799286 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06863233 | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00720785 | Natural Killer Cells and Bortezomib to Treat Cancer | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01167530 | Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer(RAD001) | completed | Phase 1 | 26 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04858958 | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation(FAVOUR) | completed | Phase 1 | 90 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | completed | Phase 1 | 94 | Compugen LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06532032 | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer(swalloWTail) | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04919369 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 18 | Dwight OwenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects(STILE) | completed | Phase 1 / Phase 2 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04487756 | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer(VENEZO-LUNG) | completed | Phase 1 / Phase 2 | 20 | Instituto Oncológico Dr RosellOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06049966 | Atezolizumab in Large Cell Neuroendocrine Carcinoma(LANCE) | completed | Phase 1 | 22 | Oncology Center of Biochemical Education And ResearchOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06386653 | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT00453154 | Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04181788 | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 155 | PfizerINDUSTRY | 6 | Jun 15, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
| NCT00238628 | A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Stanford UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06713564 | A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer | completed | Phase 1 | 24 | Integro TheranosticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03758287 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | completed | Phase 1 / Phase 2 | 108 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01802632 | AZD9291 First Time In Patients Ascending Dose Study(AURA) | completed | Phase 1 / Phase 2 | 603 | AstraZenecaINDUSTRY | 10 | Apr 20, 2026 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials